This is my second Travere Therapeutics (NASDAQ: TVTX ) article following 01/2024's "Travere Therapeutics: Restructuring Away From Disaster". In Restructuring, I rated Travere as a "Hold". Its referenced restructuring plan has worked quite well with shares trading up ~81%.Writing under the pseudonym "out of ignorance", I very much regard investing as a learning process. Investing failures are tuition paid. Investing successes enter the trove of lessons learned. In my Seeking Alpha articles I share my experie ...